<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7307801\results\search\disease\results.xml">
  <result pre="equation-count: ref-count: page-count: In recent months, the pandemic caused by" exact="Severe" post="Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) produced serious consequences in terms"/>
  <result pre="ref-count: page-count: In recent months, the pandemic caused by Severe" exact="Acute" post="Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) produced serious consequences in terms of"/>
  <result pre="page-count: In recent months, the pandemic caused by Severe Acute" exact="Respiratory" post="Syndrome-Coronavirus-2 (SARS-CoV-2) produced serious consequences in terms of both"/>
  <result pre="are asymptomatic [2]. However, in about 20% of patients the" exact="disease" post="causes severe clinical consequences that require hospitalization and, in"/>
  <result pre="average [5]. Individual factors influencing the natural history of the" exact="disease" post="could cause such dissimilar clinical outcomes. To date there"/>
  <result pre="COVID-19 and treating them with antivirals during early stages of" exact="infection" post="could be one strategy to manage the pandemic. COVID-19"/>
  <result pre="mechanisms with previous epidemics caused by SARS-CoV and Middle East" exact="Respiratory" post="Syndrome (MERS)-CoV. As with SARS and MERS, the course"/>
  <result pre="with previous epidemics caused by SARS-CoV and Middle East Respiratory" exact="Syndrome" post="(MERS)-CoV. As with SARS and MERS, the course of"/>
  <result pre="â€œviralâ€� phase when cells are infected by the virus, the" exact="viral" post="load increases rapidly and the host's immune response is"/>
  <result pre="inflammatory response, therefore causing serious damage to the lungs, kidneys" exact="and heart" post="[10,11]. A common feature of coronaviruses is to replicate"/>
  <result pre="response, therefore causing serious damage to the lungs, kidneys and" exact="heart" post="[10,11]. A common feature of coronaviruses is to replicate"/>
  <result pre="in vitro and in vivo [12,13]. In SARS-CoV infections, high" exact="viral" post="loads measured in early stages of the disease are"/>
  <result pre="infections, high viral loads measured in early stages of the" exact="disease" post="are associated with increased mortality [13]. Both SARS-CoV and"/>
  <result pre="response of monocytes-macrophages [16]. Studies in animal models of SARS-CoV" exact="infection" post="have shown that intense virus replication associated with reduced"/>
  <result pre="with reduced production of INF I during early stages of" exact="infection" post="are associated with subsequent development of lung damage and"/>
  <result pre="lethality [15]. The host's delayed immune response associated with increased" exact="viral" post="replication promotes a progressive accumulation of inflammatory cells such"/>
  <result pre="cells are not appropriately modulated, the â€œimmuneâ€� phase of the" exact="disease" post="is triggered and a â€œcytokine stormâ€� is generated [18]."/>
  <result pre="meta-analysis of thirteen retrospective studies conducted in China (on a" exact="total" post="of 3027 patients) has shown that age &amp;gt;65 years"/>
  <result pre="constitute independent risk factors for severe forms/ mortality from COVID:" exact="hypertension" post="(ORâ€‰=â€‰2.72), diabetes (ODâ€‰=â€‰3.68), cardiovascular disease (ORâ€‰=â€‰5.19), respiratory disease (ORâ€‰=â€‰5.15)"/>
  <result pre="risk factors for severe forms/ mortality from COVID: hypertension (ORâ€‰=â€‰2.72)," exact="diabetes" post="(ODâ€‰=â€‰3.68), cardiovascular disease (ORâ€‰=â€‰5.19), respiratory disease (ORâ€‰=â€‰5.15) [22]. Another"/>
  <result pre="for severe forms/ mortality from COVID: hypertension (ORâ€‰=â€‰2.72), diabetes (ODâ€‰=â€‰3.68)," exact="cardiovascular disease" post="(ORâ€‰=â€‰5.19), respiratory disease (ORâ€‰=â€‰5.15) [22]. Another meta-analysis of six"/>
  <result pre="severe forms/ mortality from COVID: hypertension (ORâ€‰=â€‰2.72), diabetes (ODâ€‰=â€‰3.68), cardiovascular" exact="disease" post="(ORâ€‰=â€‰5.19), respiratory disease (ORâ€‰=â€‰5.15) [22]. Another meta-analysis of six"/>
  <result pre="mortality from COVID: hypertension (ORâ€‰=â€‰2.72), diabetes (ODâ€‰=â€‰3.68), cardiovascular disease (ORâ€‰=â€‰5.19)," exact="respiratory" post="disease (ORâ€‰=â€‰5.15) [22]. Another meta-analysis of six studies conducted"/>
  <result pre="from COVID: hypertension (ORâ€‰=â€‰2.72), diabetes (ODâ€‰=â€‰3.68), cardiovascular disease (ORâ€‰=â€‰5.19), respiratory" exact="disease" post="(ORâ€‰=â€‰5.15) [22]. Another meta-analysis of six studies conducted in"/>
  <result pre="Another meta-analysis of six studies conducted in China (on a" exact="total" post="of 1558 patients) confirmed that the previous pathologies, as"/>
  <result pre="1558 patients) confirmed that the previous pathologies, as well as" exact="cerebrovascular disease" post="(ORâ€‰=â€‰3.89), constitute independent risk factors for severe forms /"/>
  <result pre="patients) confirmed that the previous pathologies, as well as cerebrovascular" exact="disease" post="(ORâ€‰=â€‰3.89), constitute independent risk factors for severe forms /"/>
  <result pre="of at least one of the following pathologies: hypertension, diabetes," exact="respiratory" post="diseases, cardiovascular disease, cerebrovascular disease. Subjects with at least"/>
  <result pre="least one of the following pathologies: hypertension, diabetes, respiratory diseases," exact="cardiovascular disease," post="cerebrovascular disease. Subjects with at least two of these"/>
  <result pre="of the following pathologies: hypertension, diabetes, respiratory diseases, cardiovascular disease," exact="cerebrovascular disease." post="Subjects with at least two of these three factors"/>
  <result pre="patient) â‰¥2 out of 3 (high risk patient) *Hypertension, diabetes," exact="cardiovascular disease," post="respiratory diseases, cerebrovascular disease [22,23]. Individuals at risk could"/>
  <result pre="out of 3 (high risk patient) *Hypertension, diabetes, cardiovascular disease," exact="respiratory" post="diseases, cerebrovascular disease [22,23]. Individuals at risk could be"/>
  <result pre="3 (high risk patient) *Hypertension, diabetes, cardiovascular disease, respiratory diseases," exact="cerebrovascular disease" post="[22,23]. Individuals at risk could be sorted from national"/>
  <result pre="(high risk patient) *Hypertension, diabetes, cardiovascular disease, respiratory diseases, cerebrovascular" exact="disease" post="[22,23]. Individuals at risk could be sorted from national"/>
  <result pre="from national or regional health databases through simple search filters." exact="General" post="practitioners working in the first line of home intervention"/>
  <result pre="intervention could thus identify subjects at risk among their patients." exact="General" post="practitioners could then verify the health conditions of patients,"/>
  <result pre="mortality, while late-stage treatment does not improve survival [8,9]. The" exact="biphasic" post="nature of COVID-19, as already shown in SARS [6,7],"/>
  <result pre="of symptoms. Ideally, high-risk patients should start treatment immediately after" exact="disease" post="is confirmed by nasopharyngeal swabs. However, if it is"/>
  <result pre="and of possible interactions with other drugs. For patients with" exact="macular degeneration," post="for example, it would be preferable to use LPV/RTV"/>
  <result pre="LPV/RTV rather than CH/HCH even if the risk of worsening" exact="retinal disease" post="in short-term treatments with HCH is low [33]. CH/HCH"/>
  <result pre="rather than CH/HCH even if the risk of worsening retinal" exact="disease" post="in short-term treatments with HCH is low [33]. CH/HCH"/>
  <result pre="regions of the world become available. Early antiviral treatment of" exact="symptomatic" post="patients at risk could result in a reduction in"/>
  <result pre="2020 Apr 16. 10.1002/jmv.25894 2MizumotoKKagayaKZarebskiAChowellGEstimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the Diamond Princess cruise"/>
  <result pre="McGoogan JM. Characteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: Summary of a Report"/>
  <result pre="Report of 72 314 Cases From the Chinese Center for" exact="Disease" post="Control and Prevention. JAMA. 2020 Feb 24. https://jamanetwork.com/journals/jama/fullarticle/2762130. 4LaiCCShihTPKoWCTangHJHsuehPRSevere"/>
  <result pre="Disease Control and Prevention. JAMA. 2020 Feb 24. https://jamanetwork.com/journals/jama/fullarticle/2762130. 4LaiCCShihTPKoWCTangHJHsuehPRSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19)."/>
  <result pre="Control and Prevention. JAMA. 2020 Feb 24. https://jamanetwork.com/journals/jama/fullarticle/2762130. 4LaiCCShihTPKoWCTangHJHsuehPRSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19). The"/>
  <result pre="and Prevention. JAMA. 2020 Feb 24. https://jamanetwork.com/journals/jama/fullarticle/2762130. 4LaiCCShihTPKoWCTangHJHsuehPRSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19). The epidemic"/>
  <result pre="5ChenGWuDGuoWCaoYHuangDWangHet al.Clinical and immunological features of severe and moderate coronavirus" exact="disease" post="2019.J Clin Invest. 2004;130:2620-9. 10.1172/JCI13724432217835 6ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe"/>
  <result pre="disease 2019.J Clin Invest. 2004;130:2620-9. 10.1172/JCI13724432217835 6ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
  <result pre="2019.J Clin Invest. 2004;130:2620-9. 10.1172/JCI13724432217835 6ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.Hong"/>
  <result pre="Clin Invest. 2004;130:2620-9. 10.1172/JCI13724432217835 6ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort study.Hong Kong"/>
  <result pre="10.1136/thorax.2003.01265814985565 8CaoBWangYWenDLiuWWangJFanGet al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19.N Engl J Med. 2020;382:1787-99. 10.1056/NEJMoa200128232187464 9WuJLiWShiXChenZJiangBLiuJet al.Early antiviral"/>
  <result pre="severity and improve the prognosis of patients with novel coronavirus" exact="disease" post="(COVID-19).J Intern Med. 2020.Online ahead of print. 10.1111/joim.1306332220033 10CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman"/>
  <result pre="Med. 2020.Online ahead of print. 10.1111/joim.1306332220033 10CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman immunopathogenesis of severe" exact="acute" post="respiratory syndrome (SARS).Virus Res. 2008;133:13-9. 10.1016/j.virusres.2007.02.01417374415 11PedersenSFHoYCSARS-CoV-2: a storm"/>
  <result pre="2020.Online ahead of print. 10.1111/joim.1306332220033 10CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman immunopathogenesis of severe acute" exact="respiratory" post="syndrome (SARS).Virus Res. 2008;133:13-9. 10.1016/j.virusres.2007.02.01417374415 11PedersenSFHoYCSARS-CoV-2: a storm is"/>
  <result pre="ahead of print. 10.1111/joim.1306332220033 10CameronMJBermejo-MartinJFDaneshAMullerMPKelvinDJHuman immunopathogenesis of severe acute respiratory" exact="syndrome" post="(SARS).Virus Res. 2008;133:13-9. 10.1016/j.virusres.2007.02.01417374415 11PedersenSFHoYCSARS-CoV-2: a storm is raging.J"/>
  <result pre="in Vero E6 cells.J Gen Virol. 2003;84:3291-303. 10.1099/vir.0.19505-014645910 13ChuCMPoonLLChengVCChanKSHungIFWongMMet al.Initial" exact="viral" post="load and the outcomes of SARS.CMAJ. 2004;171:1349-52. 10.1503/cmaj.104039815557587 14ThielVWeberFInterferon"/>
  <result pre="to SARS-coronavirus infection.Cytokine Growth Factor Rev. 2008;19:121-32. 10.1016/j.cytogfr.2008.01.00118321765 15ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKet al.Dysregulated" exact="Type I" post="interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in"/>
  <result pre="al.Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal" exact="pneumonia" post="in SARS-CoV-infected mice.Cell Host Microbe. 2016;19:181-93. 10.1016/j.chom.2016.01.00726867177 16KimKDZhaoJAuhSYangXDuPTangHet al.Adaptive"/>
  <result pre="2016;19:139-41. 10.1016/j.chom.2016.01.01226867172 18WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndrome.Clin Exp Immunol. 2004;136:95-103. 10.1111/j.1365-2249.2004.02415.x15030519 19LeungGMHedleyAJHoLMChauPWongIOLThachTQet al.The epidemiology"/>
  <result pre="10.1016/j.chom.2016.01.01226867172 18WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndrome.Clin Exp Immunol. 2004;136:95-103. 10.1111/j.1365-2249.2004.02415.x15030519 19LeungGMHedleyAJHoLMChauPWongIOLThachTQet al.The epidemiology of"/>
  <result pre="syndrome.Clin Exp Immunol. 2004;136:95-103. 10.1111/j.1365-2249.2004.02415.x15030519 19LeungGMHedleyAJHoLMChauPWongIOLThachTQet al.The epidemiology of severe" exact="acute" post="respiratory syndrome in the 2003 Hong Kong epidemic: an"/>
  <result pre="Exp Immunol. 2004;136:95-103. 10.1111/j.1365-2249.2004.02415.x15030519 19LeungGMHedleyAJHoLMChauPWongIOLThachTQet al.The epidemiology of severe acute" exact="respiratory" post="syndrome in the 2003 Hong Kong epidemic: an analysis"/>
  <result pre="Immunol. 2004;136:95-103. 10.1111/j.1365-2249.2004.02415.x15030519 19LeungGMHedleyAJHoLMChauPWongIOLThachTQet al.The epidemiology of severe acute respiratory" exact="syndrome" post="in the 2003 Hong Kong epidemic: an analysis of"/>
  <result pre="patients.Ann Intern Med. 2004;141:662-73. 10.7326/0003-4819-141-9-200411020-0000615520422 20RiversCMMajumderMSLofgrenETRisks of death and severe" exact="disease" post="in patients with Middle East Respiratory Syndrome Coronavirus, 2012-2015.Am"/>
  <result pre="of death and severe disease in patients with Middle East" exact="Respiratory" post="Syndrome Coronavirus, 2012-2015.Am J Epidemiol. 2016;184:460-4. 10.1093/aje/kww01327608662 21SARS-CoV-2 Surveillance"/>
  <result pre="death and severe disease in patients with Middle East Respiratory" exact="Syndrome" post="Coronavirus, 2012-2015.Am J Epidemiol. 2016;184:460-4. 10.1093/aje/kww01327608662 21SARS-CoV-2 Surveillance Group."/>
  <result pre="meta-analysis.Aging (Albany NY). 2020;12:6049-57.32267833 24MartinezMACompounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirus.Antimicrob Agents Chemother. 2020;64:e00399-20. 10.1128/AAC.00399-2032152082 25LiGDe ClercqETherapeutic options"/>
  <result pre="10.1038/d41573-020-00016-032127666 26VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread.Virol J. 2005;2:69. 10.1186/1743-422X-2-6916115318 27YaoXYeFZhangMCuiCHuangBNiuPet al.In vitro antiviral"/>
  <result pre="of optimized dosing design of hydroxychloroquine for the treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020;ciaa237."/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020;ciaa237. Online"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020;ciaa237. Online ahead"/>
  <result pre="design of hydroxychloroquine for the treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020;ciaa237. Online ahead of"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro.Cell Discov. 2020;6:16. 10.1038/s41421-020-0156-032194981 29ChoyKTWongAYKaewpreedeePSiaSFChenDHuiKPYet al.Remdesivir, lopinavir, emetine,"/>
  <result pre="2020;178:104786. 10.1016/j.antiviral.2020.10478632251767 30GaoJHuSUpdate on use of chloroquine/hydroxychloroquine to treat coronavirus" exact="disease" post="2019 (COVID-19).Biosci Trends. 2020;14:156-8. 10.5582/bst.2020.0307232281583 31GautretPLagierJCParolaPHoangVTMeddebLSevestreJet al.Clinical and microbiological"/>
 </snippets>
</snippetsTree>
